Presenter: Jasmina Radoicic, PhD, Senior Scientist
RNA therapeutics are rapidly expanding across a wide range of applications, including oncology, infectious diseases, rare diseases, cardiovascular disease, and autoimmune diseases. Central to RNA manufacturing is the in vitro transcription (IVT), a method that uses RNA polymerases to synthesize RNA. To reduce manufacturing costs and unwanted immuno stimulatory products, Primrose Bio developed the Prima RNApols®, a portfolio of engineered RNA polymerases, designed to integrate effortlessly into early and late-stage mRNA workflows. The Prima RNA polymerases are designed to deliver on key performance indicators: yield, integrity, capping efficiency, and ultra-low double stranded RNA (dsRNA), increasing translation in human cell lines and lowering immuno stimulatory effects.
Primrose Bio’s Prima RNApols® are built on an enzyme evolution platform based on ultra-high throughput screens and protein-engineering approaches. The wealth of data generated by the evolution platform places our enzyme portfolio in a favorable position to address future manufacturing challenges and support the development of next generation of mRNA therapeutics.
